Skip to main content
EJNMMI Research
Fig. 6 | EJNMMI Research

Fig. 6

From: 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study

Fig. 6

Clearance of radioactivity (kBq/ml) from the blood for all individual patients. The mean curve represents the calculated mean clearance from the blood according to a two-compartment model. Activities are decay corrected to the time of injection. A distribution half-life of 1.2 h (SD 1.5) and an elimination half-life of 26.9 h (SD 2.7) were estimated

Back to article page